Trovagene Inc. (NASDAQ: TROV) Starts Presentation at NobleCon16
Trovagene (NASDAQ: TROV) is a clinical-stage Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including solid tumors, leukemias and lymphomas. Trovagene has intellectual property and proprietary technology that enables the company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. For more information, visit the company’s website at https://www.trovageneoncology.com About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company…